economy
Buy these small-cap stocks set for big gains in the spring, says Oppenheimer
The small-cap Russell 2000 ended March with losses of more than 5%, but the firm has spotted a few names that could see a surge.
TL;DR
- Oppenheimer has identified 30 small- or mid-cap stocks (market caps $1B-$12B) that could see strong rallies this spring.
- Alumis, a biotechnology company, is highlighted for its best year-to-date performance (doubled already in 2026) and has a $55 price target, suggesting a potential 150% gain.
- Nurix Therapeutics, focusing on cancer and autoimmune diseases, has an analyst price target of $28, representing an 80% potential gain despite a recent 18% drop.
- DigitalOcean, a cloud platform company, is viewed as a turnaround story with potential for multi-year expansion, and an analyst has set a $100 price target, implying over 16% growth.
- Alumis's success is attributed to positive trial results for its envudeucitinib drug for plaque psoriasis.